<!--
title: A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
description: doi: 10.1016/j.ijid.2020.11.191. 
published: true
date: 2022-02-11T12:38:46.827Z
tags: #effects, #ivermectin, #efficiacy, #doxycyline, #double, #blinded, #placebo, #controlled, #bangladesh
editor: ckeditor
dateCreated: 2022-01-07T15:35:18.763Z
-->

<p>Randomized Controlled Trial</p>
<p>Int J Infect Dis</p>
<p>&nbsp;2021 Feb;103:214-216.</p>
<p>doi: 10.1016/j.ijid.2020.11.191. Epub 2020 Dec 2.</p>
<h1><strong>A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness</strong></h1>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Ahmed+S&amp;cauthor_id=33278625">Sabeena Ahmed</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33278625/#affiliation-1"><sup>1</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Karim+MM&amp;cauthor_id=33278625">Mohammad Mahbubul Karim</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33278625/#affiliation-1"><sup>1</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Ross+AG&amp;cauthor_id=33278625">Allen G Ross</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33278625/#affiliation-1"><sup>1</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Hossain+MS&amp;cauthor_id=33278625">Mohammad Sharif Hossain</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33278625/#affiliation-1"><sup>1</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Clemens+JD&amp;cauthor_id=33278625">John D Clemens</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33278625/#affiliation-1"><sup>1</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sumiya+MK&amp;cauthor_id=33278625">Mariya Kibtiya Sumiya</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33278625/#affiliation-1"><sup>1</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Phru+CS&amp;cauthor_id=33278625">Ching Swe Phru</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33278625/#affiliation-1"><sup>1</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Rahman+M&amp;cauthor_id=33278625">Mustafizur Rahman</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33278625/#affiliation-1"><sup>1</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Zaman+K&amp;cauthor_id=33278625">Khalequ Zaman</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33278625/#affiliation-1"><sup>1</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Somani+J&amp;cauthor_id=33278625">Jyoti Somani</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33278625/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Yasmin+R&amp;cauthor_id=33278625">Rubina Yasmin</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33278625/#affiliation-3"><sup>3</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Hasnat+MA&amp;cauthor_id=33278625">Mohammad Abul Hasnat</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33278625/#affiliation-4"><sup>4</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Kabir+A&amp;cauthor_id=33278625">Ahmedul Kabir</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33278625/#affiliation-5"><sup>5</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Aziz+AB&amp;cauthor_id=33278625">Asma Binte Aziz</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33278625/#affiliation-1"><sup>1</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Khan+WA&amp;cauthor_id=33278625">Wasif Ali Khan</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/33278625/#affiliation-6"><sup>6</sup></a></p>
<p>Affiliations expand</p>
<ul>
  <li>PMID: <strong>33278625</strong></li>
  <li>PMCID: <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7709596/">PMC7709596</a></li>
  <li>DOI: <a href="https://doi.org/10.1016/j.ijid.2020.11.191">10.1016/j.ijid.2020.11.191</a></li>
</ul>
<p><strong>Free PMC article</strong></p>
<h2><strong>Abstract</strong></h2>
<p>Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three groups: oral ivermectin alone (12 mg once daily for 5 days), oral ivermectin in combination with doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days), and a placebo control group. Clinical symptoms of fever, cough, and sore throat were comparable among the three groups. Virological clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but this was not the case for the ivermectin + doxycycline arm (11.5 days; p = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings.</p>
<p><strong>Keywords: </strong>Bangladesh; COVID-19; Doxycycline; Ivermectin; SARS-CoV-2.</p>
<p>&nbsp;</p>
<p>Source: https://pubmed.ncbi.nlm.nih.gov/33278625/</p>
